| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
12,639 |
10,920 |
$926K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
12,951 |
10,943 |
$895K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
29,990 |
28,833 |
$805K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
29,958 |
28,801 |
$805K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
22,218 |
21,269 |
$586K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
27,441 |
26,615 |
$563K |
| 81513 |
|
6,676 |
6,315 |
$556K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
21,201 |
17,962 |
$482K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
14,233 |
13,850 |
$385K |
| 87653 |
|
8,514 |
8,091 |
$224K |
| 87481 |
|
7,595 |
7,149 |
$198K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,265 |
1,227 |
$117K |
| 88141 |
|
5,980 |
5,804 |
$106K |
| 88377 |
|
200 |
195 |
$57K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
931 |
844 |
$51K |
| 87081 |
|
8,537 |
8,113 |
$42K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
794 |
725 |
$34K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,682 |
1,452 |
$34K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
192 |
183 |
$25K |
| 87625 |
|
462 |
452 |
$12K |
| 87563 |
|
252 |
239 |
$6K |
| 87800 |
|
129 |
126 |
$5K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
35 |
34 |
$677.50 |
| 87480 |
|
14 |
13 |
$268.02 |
| 87510 |
|
14 |
13 |
$267.84 |
| 87660 |
|
14 |
13 |
$247.08 |
| 0831T |
|
12 |
12 |
$0.00 |